Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrates that dermal white adipose tissue regulates human hair growth and pigmentation through hepatocyte growth factor secretion, highlighting potential therapeutic targets for hair-related disorders.

This study found that knocking down the gene SFRP1 in human hair follicles ex vivo prolonged the hair growth phase and increased keratinocyte proliferation, suggesting potential as a therapeutic target for maintaining hair growth in male pattern baldness, while DKK1 knockdown showed no effect.

This study demonstrated that PGF 2α significantly stimulates hair growth in human hair follicles via a receptor-driven mechanism, with a notably stronger response in intermediate follicles than in terminal ones, suggesting potential clinical significance for conditions like alopecia.

This review reports that regenerative medicine, such as autologous stem cell micrografting and Rigenera®, may significantly improve hair density in individuals with androgenetic alopecia, highlighting its potential as a future therapeutic option that addresses current treatment limitations.

This study found that both marine and bovine collagen peptides may help prevent hair loss by supporting epithelial hair follicle stem cell functions, with marine peptides maintaining hair in the growth phase and bovine peptides increasing stem cell presence in hair follicle regions.

This source reviews the potential of 3D printing, biomaterials, and smart sensors in tissue engineering, noting their application in creating artificial membranes for skin and tissue regeneration and assessing their strengths and limitations for wound dressing development and disease modeling.

This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.

In this study, researchers evaluated hair follicle transplantation techniques and reported that challenges such as limited follicle supply and low follicle survival rates often limit patient satisfaction, but advances in regenerative medicine may offer promising new solutions.

This review summarizes existing knowledge on androgenetic alopecia, including its epidemiology, pathophysiology, and management, but presents no new research findings.

This study found that ILC1-like cells can induce alopecia areata symptoms in both ex vivo human hair follicles and in vivo mouse models, challenging the view that alopecia areata is solely CD8+ T cell-driven.

This study found that GPC1 is a key regulator of angiogenesis in human dermal microvascular endothelial cells, influenced by factors secreted by keratinocytes, and may be a target for alopecia treatment research.

This ex vivo study found that hair follicles in female pattern hair loss exhibited nutrient insufficiency and dormant metabolism, but maintained nutrient uptake capability, suggesting potential benefits of nutritional supplementation as an adjunct therapy.

This article discusses managing extensive hair loss with limited transplant options and suggests a frontal forelock-type pattern is effective for both already bald men and younger patients at risk; it reports no new clinical results.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review discusses current medical and surgical treatments for androgenetic alopecia, highlighting the use of finasteride and minoxidil for men and the role of hair transplantation techniques, without providing new clinical results.

This abstract explains that androgenetic alopecia, a common hair loss disorder influenced by genetics and hormones like dihydrotestosterone, has FDA-approved treatments including minoxidil, finasteride, and photolaser therapy, but its genetic basis and susceptibility to environmental factors remain complex.

Higher levels of MiR-92a-1-5p and miR-328-3p found in female hair loss patients.

In this phase I/II clinical trial, placenta-derived mesenchymal stem cell exosome therapy significantly improved hair density and diameter, and reduced hair loss in patients with androgenetic alopecia, though further large-scale studies are needed to confirm these results and investigate the underlying molecular mechanisms.

The document concludes that hair transplant methods are often selected for provider convenience over patient benefit, highlighting the need for less invasive techniques and careful physician involvement for better results.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

This review discusses the clinical, epidemiological, and pathophysiological aspects of female pattern hair loss, reporting no new research findings.

This review discusses female pattern hair loss, its psychological impact, and available treatments but provides no new clinical findings; the authors emphasize early intervention for better outcomes.

This paper discusses spironolactone as a potential off-label treatment for female pattern hair loss, noting its ability to halt hair loss progression and induce partial regrowth in a significant number of women but reports no new clinical results.

This review discusses treatment options for female pattern hair loss, emphasizing the importance of early intervention and the benefits of combined therapies, but reports no new clinical results.

This case report described cosmetically significant hair regrowth in a 39-year-old woman with permanent chemotherapy-induced alopecia after continuous oral minoxidil use.

This review discusses treatment options for androgenetic alopecia in men and women, highlighting minoxidil and finasteride, without presenting new clinical findings.

This study found that miniaturized hair follicles from pattern alopecia can regenerate rapidly when transplanted onto mice and may grow as well as or better than terminal hairs.

Over 50% of women over 50 experience hair loss, with minoxidil being the only proven effective treatment.

This study found that combining drug therapy with hair grafts can regress male androgenetic alopecia from Hamilton type V to type III.

This article discusses the cell therapy potential of follicular cell implantation for hair regeneration and reports no new clinical results, emphasizing the role of dermal papilla cells in forming new follicles.